The ADHD Drug That Has Nothing to Do With Stimulants
Alkermes just dropped early data on ALKS 7290, a drug that treats ADHD through an entirely different brain system than any existing therapy. It's the first time an orexin agonist has shown clinical benefit in ADHD, and the implications for a $17+ billion market are hard to ignore.
A Completely Different Playbook
For decades, treating ADHD has been a one-trick pony. Got attention problems? Here's a stimulant. Can't tolerate the stimulant? Here's a weaker non-stimulant that probably won't work as well. That's been the menu.
Alkermes just walked into the restaurant with a dish nobody's seen before.
The company reported Phase 1b proof-of-concept data for ALKS 7290, a drug that works through an entirely different brain system than anything currently prescribed for ADHD. In 50 adults with the condition, the drug showed dose-dependent symptom improvement over 14 days, with no serious side effects. It's early. It's small. But the mechanism is what makes this genuinely interesting.
ALKS 7290 is an orexin 2 receptor agonist. If that means nothing to you, don't worry. We'll get there.
Your Brain's Thermostat for Alertness
Think of orexin as the thermostat that controls your brain's state of alertness. Orexin neurons sit in the hypothalamus and send signals to basically every arousal system you have: dopamine, norepinephrine, serotonin, histamine, acetylcholine. When the thermostat works properly, you can sustain focused wakefulness. When it breaks completely, you get narcolepsy.
But what if the thermostat isn't broken, just miscalibrated?
That's the hypothesis behind using an orexin agonist for ADHD. Researchers have found that some children with ADHD have lower levels of orexin in their blood, particularly those with the inattentive subtype. If your brain can't maintain a stable alert state, it makes sense that you'd struggle with attention, executive function, and the kind of sustained focus that ADHD patients find so elusive.
This also explains something clinicians have noticed for years: ADHD and sleep problems overlap constantly. Daytime sleepiness, circadian rhythm issues, trouble falling asleep. If orexin is the common thread connecting wakefulness to attention, tweaking that system could address both.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The Phase 1b trial tested two doses (20 mg and 50 mg daily) in adults with ADHD. The primary goal was safety, but Alkermes also measured symptom changes using standard rating scales.
On the AISRS (a clinician-rated ADHD symptom scale), the median score dropped 14 points at the lower dose and 19 points at the higher dose after just two weeks. That's a meaningful signal for such a short trial.
The CGI-S, which rates overall illness severity, showed shifts consistent with patients moving from more severe to milder categories. Most side effects were mild, and no serious adverse events were reported. Some patients showed improvement as early as day six.
Now, the necessary caveats: this was 50 people over 14 days. There's no published placebo comparison from this readout. Phase 1b studies are designed to show that a drug is safe and might work, not to prove efficacy. Alkermes knows this, which is why it's already running a Phase 2 trial with 312 adults, with data expected in 2027.
Why Wall Street Is Paying Attention
The ADHD market is enormous, somewhere in the range of $17 to $19 billion globally in 2026 by most estimates. Stimulants still dominate, capturing approximately 90% of prescriptions. And while they work for many patients, they come with baggage: abuse potential, Schedule II restrictions that complicate prescribing, side effects that drive many patients to quit.
Non-stimulant options exist (atomoxetine, guanfacine, clonidine), but they're generally viewed as less effective than stimulants. The field has been waiting for something that could match stimulant-level efficacy without the stimulant-level downsides. That's the theoretical promise of an orexin agonist.
Analysts have started using words like "blockbuster" and "major upside" around Alkermes' orexin platform. The company itself has described the program as a potential "company changer," which is bold language for a Phase 1b readout. But the logic tracks: if you could crack ADHD with a non-scheduled, non-stimulant drug that works through a novel mechanism, you'd be looking at a genuinely differentiated product in a market starving for alternatives.
Alkermes' Bigger Bet on Orexin
ALKS 7290 isn't a one-off. Alkermes has built an entire orexin platform, and the ADHD program is just one branch of it.
The company's lead orexin asset is alixorexton, currently in Phase 3 trials for narcolepsy types 1 and 2, with a Phase 2 study in idiopathic hypersomnia (a condition where people are excessively sleepy for no identifiable reason). There's also ALKS 4510, targeting fatigue in multiple sclerosis and Parkinson's disease.
Management has framed this as evolving from a sleep-medicine program into a broader "neurocircuitry platform." The idea is that orexin sits at the intersection of so many brain functions (arousal, attention, motivation, reward) that agonizing the receptor could be useful across multiple neurological and psychiatric conditions.
It's an ambitious thesis. The commercial backbone right now comes from marketed products like LUMRYZ, while orexin is positioned as the long-term growth engine.
The Ghosts of Orexin Past
Before you get too excited, a quick history lesson. The orexin agonist field has had its stumbles.
Takeda's TAK-994 showed strong efficacy in narcolepsy patients but was discontinued due to liver toxicity. That setback sent a chill through the space and forced developers to engineer safer next-generation molecules. It's a reminder that even when the biology is right, the chemistry has to cooperate.
The field has since recovered. Takeda's follow-up compound, oveporexton, has been approved, and multiple other orexin agonists are in late-stage development. But the TAK-994 episode is worth remembering as ALKS 7290 moves into larger, longer trials. Fourteen days of clean safety data is encouraging; it's not the whole story.
The Bottom Line
Alkermes has the first clinical evidence that an orexin receptor agonist can improve ADHD symptoms. That's a genuinely novel finding. Nobody has shown this before in humans.
But "first clinical evidence" and "proven treatment" are separated by years of larger trials, regulatory scrutiny, and the ever-present risk that early promise fades with scale. The Phase 2 data in 2027 will be the real test.
If it works, though? A non-stimulant, non-scheduled drug that treats ADHD through an entirely new mechanism would be one of the most significant additions to psychiatric pharmacology in years. The thermostat theory of ADHD is officially being tested, and the first readings look promising.
Clinical & Regulatory
4 min read
Sarepta's Worst Week Just Rewrote the Gene Therapy Playbook
Sarepta slapped a black box warning on its Duchenne gene therapy Elevidys and cut 36% of its workforce in one brutal announcement. The fallout raises hard questions about the commercial future of accelerated-approval gene therapies in rare disease.
